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Abstract:
Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes 
significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse 
outcomes in this population, including poor quality of life, hepatic decompensation, mortality in 
patients with cirrhosis evaluated for LT, longer hospital and intensive care unit stay, higher 
incidence of infection following LT, and higher overall health care cost. While it is clear that muscle 
mass is an important predictor of LT outcomes, many questions remain, including the best modality 
for assessing muscle mass, the optimal cut-off values for sarcopenia, the ideal timing and frequency 
of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical 
decision making.  For that reason, we assembled a group of experts to form the North American 
Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature 
to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia 
assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. 
Skeletal muscle index (SMI) assessed by computed tomography constitutes the best studied 
technique for assessing sarcopenia in patients with cirrhosis. Cut-off values for sarcopenia, defined 
as SMI <50 cm2/m2 in male and <39 cm2/m2 in female patients constitute the validated definition for 
sarcopenia in patients with cirrhosis. The management of sarcopenia requires a multi-pronged 
approach including nutrition, exercise and additional pharmacological therapy as deemed necessary.
Future studies should evaluate whether recovery of sarcopenia with nutritional management in 
combination with an exercise program is sustainable, and how improvement in muscle mass might 
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Sarcopenia, the disproportionate loss of muscle mass, is common in patients with cirrhosis 
awaiting liver transplantation (LT). Sarcopenia has been shown to be a significant risk factor for 
waitlist mortality, postoperative complications, and post-LT death (1-5). The new international 
statistical classification of diseases and related health problems, 10th revision (ICD-10-CM) 
(M62.84) code for sarcopenia represents a significant recognition of sarcopenia as a disease (6).  
While it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, 
including the best modality for measuring muscle mass, the optimal cut-off values for sarcopenia, 
the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept 
of sarcopenia into clinical decision making.  
Therefore, in 2018, we convened a group of experts to form the North American Working 
Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address 
these outstanding questions regarding sarcopenia in LT. This document represents the product of our 
efforts to develop a statement by experts in the field on the current state of knowledge and key gaps 
for future high impact research on sarcopenia in the LT setting.
The importance of sarcopenia as a construct
Sarcopenia is a term derived from the Greek sarco (flesh) and penia (deficiency). 
Sarcopenia was initially defined as age-related loss of skeletal muscle (7), but has since been 
expanded to reflect low muscle mass leading to negative effects on physical performance and 
clinical outcomes across a broad range of disease states outside of geriatric populations. 
Conceptually, sarcopenia is only one – but likely the dominant – component of the larger 
construct of global physical dysfunction that is prevalent in patients with cirrhosis that has most 
recently been described with the term “frailty”.  While frailty is the manifesting symptom of 
impaired global physical functioning, loss of muscle mass is an obvious sign that frailty may be 
present. Sarcopenia is the metric of clinically-relevant skeletal muscle depletion that can be 
objectively measured in clinical practice and is least likely to be affected by acute illness or 
alterations in cognitive function. For this reason, our working group chose to define sarcopenia using 
only muscle mass, although we acknowledge that muscle function (e.g., grip strength) is 
incorporated into definitions of sarcopenia by other groups including the European Working Group 
on Sarcopenia in Older People and Asian Working Group for Sarcopenia (8, 9). 
Although multiple definitions of sarcopenia for patients with cirrhosis exist in the literature, 
low muscle mass, regardless of how it is measured, is a powerful predictor of clinically relevant 
adverse outcomes, including poor quality of life (10), hepatic decompensation  (11), mortality in 
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15), higher incidence of infection following LT (2, 16), higher overall health care cost (17), and 
post-LT mortality (3, 18).
Aside from being an important marker of pre and post-LT mortality, sarcopenia is associated 
with additional important clinical parameters independent of scoring systems for severity of liver 
dysfunction. Skeletal muscle plays an integral role in ammonia detoxification, and sarcopenia has 
been identified as an independent risk factor for hepatic encephalopathy (HE) in patients with 
cirrhosis (19). Other complications such as ascites and infections are more common in sarcopenic 
patients compared to non-sarcopenic patients with cirrhosis (2). 
Modalities to Evaluate Muscle Mass in the Liver Transplant Candidate 
There currently exists significant heterogeneity in the metrics used to define sarcopenia in 
the published domain. The great challenge in identifying a single standard is that many modalities 
exist for muscle mass quantification, including anthropometry, bioelectrical impedance analysis 
(BIA), dual-energy X-ray absorptiometry (DEXA), ultrasound (US), magnetic resonance imaging 
(MRI) and computed tomography (CT). The advantages and limitations of each modality as they 
relate to measurement of muscle mass in patients with end-stage liver disease (ESLD) are 
summarized in Table 1.  
We advocate for the use of CT-based skeletal muscle area, measured at the third lumbar 
vertebra on an abdominal CT scan (either non-contrast or contrast-enhanced scans are acceptable), in 
patients with cirrhosis for the following reasons (Please see example in Figure 1).  First, cross-
sectional imaging is commonly used in transplant centers to monitor for hepatocellular carcinoma 
(HCC) and to evaluate the vascular and biliary anatomy for surgical planning.  While preliminary 
reports suggest that MRI-based imaging yields equivalent results to CT scans (20), CT scans tend to 
be more widely available, of lower cost, and more rapidly performed in clinical practice. Second, the 
majority of published reports on sarcopenia in LT have used standard-of-care CT imaging, 
summarized in Table 2. Several key questions remain regarding the use of CT-based estimation of 
skeletal muscle mass, including the use of values below specific percentiles (i.e. 5th percentile) of 
age and sex-matched population or optimal cut-points for mortality discrimination, sensitivity of 
changes over time as well as the validity of measurement of psoas alone versus the total muscle area 
(21).  
Defining sarcopenia
A large, multi-center study of 396 patients with cirrhosis from five North American liver 
transplant centers established standardized cut-off values of skeletal muscle index (SMI) at <50 
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These sex-specific SMI cut-points were strongly associated with pre-LT mortality independent of 
age and MELD score (15). 
Although muscle mass has been shown in multiple studies to be associated with post-LT 
mortality (3, 18, 23), data reporting pre-LT muscle indexes associated with post-LT adverse outcome 
is limited. Recently, SMI<48 cm2/m2 in acutely ill men undergoing urgent evaluation and LT, was 
associated with higher post-LT mortality (24).
When assessing sarcopenia by SMI on an abdominal CT scan, there does not appear to be a 
large difference between measurements at L3 versus L4 vertebra (25). There is also excellent 
agreement between the various software programs (i.e. SliceOmatic, ImageJ, etc.) with respect to 
measurements of abdominal skeletal muscle area (26). 
SMI seems to be a more complete and robust measurement than individual measurement of 
the psoas muscle or the psoas muscle index (PMI), especially in men with cirrhosis. In addition, low 
PMI identifies an incomplete subset of patients at increased risk of mortality indicated by low SMI 
(21). 
While sarcopenia has classically been associated with increased mortality in both men and 
women with cirrhosis, emerging evidence suggests that sarcopenia is associated with 
disproportionately higher rates of mortality in men as compared to women (27). This emphasizes the 
importance of survival analysis stratification by sex rather than simply adjusting multivariable 
models for sex.  Furthermore, the role of ethnicity in baseline muscle mass and muscle loss has not 
yet been determined in patients with cirrhosis (28). While more data are needed, the prevalence of 
sarcopenia within each BMI category is another consideration when building a definition to 
incorporate into clinical practice. Lastly, divergent study outcomes such as overall mortality in 
evaluated patients, waitlist mortality in listed patients, post-LT mortality in patients undergoing LT, 
and short term vs. long-term outcomes, confound the comparison between published studies and 
development of generalized definitions.
Key points 
1. Standardized tools and validation between techniques are important considerations for 
the evaluation of sarcopenia in patients with end-stage liver disease awaiting LT. 
2. CT constitutes the best-studied technique for measuring sarcopenia in patients with 
cirrhosis.
3. FLEXIT (Fitness, Life Enhancement, and Exercise in Liver Transplantation 
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constitute the most robust definition for sarcopenia in patients with end-stage liver 
disease awaiting LT. 
Recommendations
1. We recommend the use of SMI as a marker of sarcopenia for outcome prediction.
2. We recommend the use of FLEXIT cut-off values to define sarcopenia in cirrhosis in 
order to characterize cohorts of patients for prospective clinical trials.
3. Future studies to define sarcopenia should be established for use in clinical practice with 
consideration of sex, age and ethnicity.
Incorporating Sarcopenia into Clinical Practice 
Although severe sarcopenia may be easy to identify visually (i.e., the “eyeball test”), 
objective and validated measures are needed to detect early stages of muscle loss, when interventions 
to slow the progression may be more effective. Ascites, obesity, and body fat distribution may render 
sarcopenia less apparent, and early stages of muscle loss are often not visually obvious. Furthermore, 
quantification of muscle mass provides objective data, which is especially critical in the setting of 
LT. 
One of the advantages of determination of muscle mass is that it can be done on cross-
sectional imaging (e.g., abdominal CT or MRI), which is often performed in LT patients as standard 
of care. Radiologists can provide total abdominal skeletal muscle area at the L3 vertebral level from 
these routine scans, from which SMI can easily be calculated. We anticipate that this will enable 
more widespread incorporation of the information provided from muscle mass measurement into 
clinical practice.
Objective assessment of sarcopenia in the LT candidate is important to two major reasons: 
1) clinical decision-making and 2) intervention. We expand upon both of these areas here.
Incorporating sarcopenia into clinical decision-making
It is important to note that the North American Working Group on Sarcopenia in Liver 
Transplantation recommends that sarcopenia should not be the sole criterion for declining or de-
listing candidates for LT. A significant limitation of utilizing sarcopenia for risk stratification is the 
lack of a threshold value of muscle loss that predicts health outcomes prohibitive for a particular 
intervention such as LT.  Furthermore, the threshold of “futility” is not universally defined but, 
instead, varies by center, clinician, and patient values. Rather, we advocate that an objective metric 
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functional and psychosocial factors of each individual patient with respect to their transplant 
candidacy as well as their own values of what a successful transplant looks like.
That being said, sarcopenia has important implications for a patient awaiting LT. At the 
minimum, in the outpatient setting, a patient with sarcopenia should be counseled that his or her 
higher risk of waitlist mortality exceeds that predicted by the MELDNa score and that they have a 
higher risk of complication after LT. This information may help to motivate the patient to seek a 
faster path to transplant, including living donor LT or to accept higher-risk donor livers. In addition, 
this information may motivate patients and providers to engage in interventions that might mitigate 
muscle loss (see next section).  
With respect to clinical decision-making, sarcopenia may hold a unique place within the 
inpatient setting where performance-based assessments of frailty may be misleading due to acute 
changes in functional performance that may not accurately reflect their underlying “steady state” 
physiologic reserve. An objective assessment of muscle mass may indicate that the patient has good 
underlying physiologic reserve that will support a full peri-operative recovery. For a patient without 
multiple risk factors for poor post-LT outcomes, sarcopenia alone is not sufficient to deny LT but 
may guide the decision about the quality of liver to accept in attempt to minimize liver-related 
complications and optimize overall patient recovery (29).  For a patient with multiple co-morbidities 
that may also negatively impact post-LT outcomes, identification of sarcopenia - in combination 
with these other medical risk factors - may be added objective evidence to not proceed with LT.
Incorporating sarcopenia into management and treatment of the LT candidate
We recommend that measurement of muscle mass best be integrated into clinical practice to 
identify patients for “prehabilitation” programs focused on optimizing nutrition and physical activity 
(30). The management of sarcopenia requires a multi-pronged approach including nutrition, exercise 
and additional pharmacological therapy as deemed necessary. The incorporation of behavioral 
change strategies while delivering nutrition (31) and exercise prescriptions (32) encourages 
exploration of the patient’s individual personal and social factors to motivate and increase the 
likelihood of patient engagement (33). We recommend the following strategies based on the current 
available evidence:
a. A nutrition prescription. At minimum, this consists of three major components:
1.  A target caloric intake recommendation. For non-obese individuals (BMI <30 kg/m2), 
the latest European Association for the Study of the Liver (EASL) Clinical Practice 
Guidelines on nutrition in chronic liver disease recommend an optimal daily energy intake of 
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tailored moderately hypocaloric diet (with a reduction of 500 to 800 kcal/day) has been 
suggested (34). The International Society for Hepatic Encephalopathy and Nitrogen 
Metabolism (ISHEN) Consensus (35) provides additional BMI-stratified target caloric 
recommendations based on an ideal body weight (also corrected for fluid retention), 
including BMI ranges of 20-30, 30-40 and >40 kg/m2. Supplemental enteral nutrition should 
be considered in hospitalized patients who are unable to meet calorie intake targets with oral 
intake alone (34, 36).
2. A target protein intake recommendation. Protein restriction is not necessary in patients 
with hepatic encephalopathy (37). Guidelines recommend a daily protein intake of 1.2-1.5 
grams/kg protein (34, 35) with further study required as to whether dairy/vegetable protein 
may have a benefit over meat protein in the setting of hepatic encephalopathy (34) and the 
variable impact of protein across the spectrum of liver disease severity.
3.  A late-evening snack recommendation.  In an attempt to shorten the overnight fasting 
period, patients are advised to take a snack shortly before bedtime or during nighttime hours 
and to eat breakfast (34, 38).  We would support the recommendation of a late-night snack 
across Child Pugh classes. The optimal composition of the late-evening snack is not clearly 
defined, with recommendations varying from branched chain amino acids (BCAA) 
containing supplements (39) to snacks containing ~50 grams of carbohydrates and 10-20 
grams of protein (31).
b)  Exercise. Although an evidence-based exercise prescription is still not available for patients 
with cirrhosis, extrapolating current knowledge from the 11 published studies on exercise in 
patients with cirrhosis (please refer to Table 4) into practice, it is recommended for patients 
to perform moderate intensity exercise for no less than 30 minutes per day, starting with a 
brief warm-up (5-10 minutes) and ending with a stretching / cool-down phase (5-10 
minutes), 3-5 times per week, aiming for a total of 150-200 minutes of exercise per week 
(32). Exercise bouts should have a duration of no less than 5-10 minutes, depending on 
disease status and tolerance, with patients commonly having to undergo multiple exercise 
bouts per day in order to accomplish these goals. In general, it is recommended that aerobic 
and resistance training be combined in a 3:2 ratio, although for the purpose of improving 
sarcopenia this ratio should favor resistance training (40).
c) Pharmacotherapy (Table 3)  
1. Vitamin D3.  Vitamin D deficiency is highly prevalent in cirrhosis and is a well-defined 

















This article is protected by copyright. All rights reserved
2. Ammonia lowering treatments. Excess ammonia delivered to muscle is the pre-eminent 
metabolic driver of sarcopenia (42).  It is reasonable to expect that current and potentially 
future ammonia lowering treatments (43, 44) to prevent encephalopathy will also be helpful 
in minimizing sarcopenia. 
3. Hormonal therapy. Standard hormonal therapy to sustain a euthyroid and euglycemic 
state defends muscle mass and function. In addition, the majority of men with advanced 
cirrhosis have hypogonadism as measured by decreased total and free testosterone levels. A 
randomized trial showed that intramuscular androgen therapy of hypogonadal cirrhotic men 
improved muscle mass, bone mass and hemoglobin A1C (45); transdermal therapy also 
appears effective with fewer potential adverse events.
4. L-Carnitine. L-carnitine is a quaternary amine (3-hydroxy-4-N-trimethylaminobutyrate) 
needed for fatty acid oxidation. Binding of L-carnitine to acetyl groups enables movement of 
acetylated fatty acids into mitochondria and their oxidation to generate energy in the form of 
ATP. Carnitine supplementation was recently reported to suppress muscle loss in an initial 
study of cirrhotic patients (46).
Key Points
1. We believe sarcopenia should not be a sole criterion on which to determine candidacy 
for LT.
2. Attaining nutritional goals appropriate for patients with cirrhosis is currently the 
predominant treatment for sarcopenia.
Recommendations
1. We recommend that the presence or absence of sarcopenia be considered as part of the 
multidisciplinary assessment in cirrhosis. 
2. Until more evidence is available, we recommend for patients with cirrhosis and 
sarcopenia to exercise 150-200 minutes per week, including both aerobic and resistance 
training (ratio favoring the latter), along with a nutritional intervention with an 
adiposity-tailored caloric intake that favors protein with key amino acids and aims to 
prevent starvation. 
3. Male patients with cirrhosis and sarcopenia are potentially eligible for pharmacologic 
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Children with irreversible liver disease offer a complex challenge to clinical care teams that 
is distinct from adults since they have a time-limited opportunity for growth and development and 
may suffer lifelong consequences if not expeditiously transplanted.  
The PELD (Pediatric End-Stage Liver Disease) score does not adequately capture waitlist 
and peri-operative risk nor the extent to which ESLD impairs functional development. Clinical 
(weight, height, anthropometrics) and biochemical (serum total protein and albumin) data fail to 
fully characterize malnutrition in chronically ill children/those with end-stage organ/liver failure and 
are often confounded. Objective nutritional biomarkers are lacking for children with ESLD.
Children with ESLD suffer from malnutrition, muscle wasting, and deconditioning that 
result from the insidious effects of underlying hepatic synthetic dysfunction and systemic 
inflammation. Broader non-laboratory assessment metrics are needed to more fully capture the 
extent of ill health status associated with chronic or end-stage liver disease in children. Pilot studies 
have demonstrated that children with ESLD have smaller psoas muscle areas than healthy controls, 
and that the psoas muscle area does not correlate with weight z-scores nor PELD score (47, 48).   
Significant gaps exist, including the (Table 5) absence of unifying definition of sarcopenia in 
growing children, the paucity of evidence to date of HOW to measure sarcopenia in children, with 
different modalities utilized, the evolving validated reference data for total psoas muscle area 
(tPMA) (via CT abdominal images) in children, the near term impact of interventions such as 
nutritional support, exercise programs etc. limited by challenges of longitudinal/serial evaluation of 
sarcopenia due to cumbersome (DEXA) or radiation heavy (CT) assessment methods, the lack of full 
understanding of how the presence of sarcopenia pre-LT affect outcomes post LT, and whether 
sarcopenia be considered in clinical decision-making.
Key Points
1. The majority of children are too young to undergo functional or performance-based 
(frailty) testing before time of liver transplantation, underscoring the special role and 
importance of muscle mass assessment in this vulnerable patient population.
2. Pilot studies demonstrate that total psoas muscle area (tPMA) increases over time until 
late adolescence and is smaller in pediatric ESLD than healthy controls.
Recommendations
1. Sarcopenia assessment should be considered in children with ESLD.  Amongst those 
pediatric patients requiring clinically indicated CT imaging, the availability of recent 
pediatric specific novel tools providing age- and sex-specific reference growth curves 
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2. Targeting non-invasive assessment strategies for children is a high needs research area.
Sarcopenia in Special Patient Populations
a. Sarcopenic obesity can be present in 20-40% of cirrhotic LT candidates (49, 50). 
Patients with sarcopenia are more likely to be obese and those with sarcopenic obesity 
are more likely to have non-alcoholic fatty liver disease as the etiology of liver disease 
(50). Of particular concern is the fact that sarcopenia can be difficult to recognize in the 
presence of obesity. Future research should include measures of obesity beyond BMI 
such as CT measures of adipose tissue.   
b. Chronic kidney disease (CKD) alone can affect muscle mass. Sarcopenia occurs in 
roughly 10% of patients with CKD alone and is associated with increased mortality (51). 
In renal transplant recipients, sarcopenia may persist for years after transplantation, with 
age and duration of dialysis being important predictors (52).  Little is known about the 
relationship between sarcopenia and CKD in LT candidates. Normal renal function in 
patients with cirrhosis has been correlated with higher measures of muscle mass (53).  
Data on measures such as duration of renal insufficiency and renal replacement therapy 
in LT candidates with sarcopenia are not available. 
Future directions for research
Sarcopenia has become a topic of prolific exploration in patients with ESLD over the last 
few years. Currently, the evaluation of sarcopenia in patients with cirrhosis appears in over 1,500 
publications. Important research questions that merit exploration for sarcopenia assessment in 
patients with ESLD include 1) the availability of reliable, accessible and practical tools to be used in 
clinical practice, 2) the optimal frequency of measurement over time, 3) how to assess the clinical 
meaning of changes over time, whether they have prognostic value independent of other 
measurements, and 4) how they can best be used to engage patients in self-motivation. 
One of the most important knowledge gaps in cirrhosis care is our limited understanding of 
the time frame associated with the efficacy of interventions. We lack information on whether 
recovery of sarcopenia with nutritional management in combination with an exercise program is 
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• 36-month mortality in 144 
men with cirrhosis (54)
• Concordance between various 
muscle mass assessment 
techniques in 59 patients with 
cirrhosis listed for LT (55)
Advantages:
• Safe, inexpensive and readily available
• Reproducible
• Low radiation exposure
Limitations:
• Failure to differentiate water from muscle, therefore 
affected by lower limb edema 
• Weak concordance between DEXA and CT in 




• Prognosis of sarcopenia  in 
161 patients with cirrhosis 
(56)
Advantages:
• Safe, rapid, easy, inexpensive
Limitations:
• Affected by fluid retention, diuretic use, liquid and 





• Development of  sarcopenia 
model in 159 patients 
evaluated for LT (57)
Advantage:
• Safe, easy, inexpensive
• No radiation exposure
• High intraobserver and interobserver reliability
Limitations:
• Reproducibility is unknown
Mid-arm 
muscle 
• Concordance between various 
muscle mass assessment 
Advantage:
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circumference 
(MAMC)
techniques in 59 patients with 
cirrhosis listed for LT (55)
• Nutritional assessment by 
Royal Free Hospital Global 
Assessment (RFH‐GA) in 232 
patients with cirrhosis listed 
for LT (23)
Limitations:
• Low intraobserver and interobserver reliability
• Affected by subcutaneous adipose tissue loss
• Weak correlation with CT determined muscle mass
CT/ MRI • MRI-based muscle 
assessment in 166 patients 
with decompensated cirrhosis 
treated with transjugular 
intrahepatic portosystemic 
shunt (TIPS) (58) 
• Development of  sarcopenia 
model in 159 patients 
evaluated for LT (57)
Advantage:
• No radiation exposure (MRI)
• Fast, accurate
• Ability to differentiate 3 main body compartments, 
i.e., muscle, visceral and subcutaneous adipose 
tissue
• Ability to identify muscle radiodensity to determine 
ectopic fat accumulation in muscle
• Appears not to be affected by the presence of ascites 
or edema
• Reduction in price and radiation exposure to only 
2.6 millisieverts by single slice CT (45)
Limitations:
• Cost
• High ionizing radiation exposure makes whole body 
CT scan unsuitable for longitudinal assessments
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2010 (1)  
 
Single TPA< 1420 mm2 at the 
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Mortality associated SMI 
cut-offs in cancer* (60)
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Mortality associated SMI 
cut-offs in 1475 patients 
with solid tumors¥ (63)
Total cross-sectional 
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TPA <1499 mm2 for men 
and <954 mm2 for women
Total psoas areas 33%
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below the 5th percentile
for each sex:
PMA <800 cm2 for men 
and <380 cm2 for women











Optimal cut-offs of 
TPMT/height to 
discriminate waiting list 
mortality
Transversal psoas muscle 
thickness [TPMT/height 
(mm/m)] at the level of 
umbilicus≤ 16.8 mm/m








Mortality associated SMI 
cut-offs in cancer* (60)
Total cross-sectional 
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SMI <39 cm2/m2 for 
women and <50 cm2/m2 
for men
abdominis, external and 










Mortality associated SMI 
cut-offs in cancer* (60)
Total cross-sectional 
areas of psoas, erector 
spinae, quadratus 
lumborum, transversus 
abdominis, external and 











Mortality associated SMI 
cut-offs in 1475 patients 
with solid tumors¥ (63)
Total cross-sectional 
areas of psoas, erector 
spinae, quadratus 
lumborum, transversus 
abdominis, external and 














L3 SMI <44.1 for men 
and <37.9 for women
Total cross-sectional 
areas of psoas, erector 
spinae, quadratus 
lumborum, transversus 
abdominis, external and 





Abbreviations: PMA, Psoas Muscle Area, PMI, Psoas Muscle Index, SMI, Skeletal Muscle Index; 
TPA, Total Psoas Area; TPMT, Transversal Psoas Muscle Thickness
*L3 SMI ≤38.5 cm2/m2 for women and ≤52.4 cm2/m2 for men
 ¥Defined as L3 SMI <=41 cm2/m2 for women and <=53 cm2/m2 for men with body mass index 
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Table 3. Pharmacotherapy for Cirrhotic Sarcopenia
Author/
Year
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Corey al., 2014 
(41)
Cholecalciferol 2000 IU/d Deficiency common in 
cirrhosis
Davuluri et al., 
2016 (43)
Tsien et al.,  2015 
(44)
Leucine 7.5 g/d typically in divided 
doses with additional amino 
acids
Included in many 
nutritional supplements














1000 mg IM, schedule per 
RCT; or transdermal gel 50 
mg/d (66)
Gel preferred for 
sustained physiologic 
levels, concerns for 
thrombosis and prostate 
cancer
Ohara et al., 2018 
(46)
L-Carnitine 1000 mg/d or BID Essential nutrient for 
fatty acid metabolism
One fourth is 
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22.5 kg (before) 
vs. 22.8 kg (after)
Patullo












45 lbs (before) vs. 
44 lbs (after)
Roman

















MAMC ↓ 0.5 cm 
in active & ↑ 0.6 
cm in control; TC 
↑ 5 cm in active¶ 
& ↓ 1 cm in 
control
Zenith















Thigh US* ↑ 0.05 
cm/m2 in active¶ 
& no change in 
control; TC ↑ 1.2 
cm in active¶ & 

















30 kg (before) to 
37 kg (after) ¶
Macias-
Rodriguez 














Phase angle ↑ 0.3 
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Roman














and risk of 
falls 
Lean mass ↑ 1.05 
kg in active & ↓ 
0.05 kg in control
Berzigotti








BIA lean mass 60 NA
HVPG and 
body weight
56.7 kg (before) 






































↑ 13% in muscle 
volume¶, ↑ 5% in 
leg strength¶, and 
↑ 10% in 
handgrip¶
Kruger









Thigh US & 
circumference
20 20 Peak VO2
Thigh US** ↑ 0.06 
cm/m2 in active¶ 
& 0.06 in control; 
TC ↑ 1.8 cm in 
active¶ & 0.6 cm 
in control
¶Denotes comparison was statistically significant
*Average feather index showed was significant in active group, whereas average compression index 
was not. 
**Average feather index showed a p=0.05 in active group, whereas average compression index was 
not significant. 
6MWT, six-minute walk test; 2MST, 2-min step tests; BCAA, branched-chain amino acids; BIA, 
bioelectrical impedance analysis; DXA, dual energy X-ray absorptiometry; HOMA-IR, Homeostatic 
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pressure gradient; kCal, kilocalories (nutritional requirement); MAMC, mid-arm muscle 
circumference; NA, not available; ONCT, open non-controlled clinical trial; RCT, randomized 
clinical trial; SMI, skeletal muscle index; TC, lower thigh circumference; US, ultrasound
Table 5. Summary of Published Literature on Sarcopenia in Pediatric Liver Disease





















Retrospective N=41 children 
post-LT (age 0.5 – 
17 years)






• SMM z-score <-2 in 41% of cohort, 
persisting up to 8 yrs post LT
• Sarcopenia associated with increased 
hospital duration and ventilator 
dependency (total PICU stay), higher 
readmission rates/LOS readmission, and 
younger age, female sex, impaired catch-
up growth at 1-year post LT
Lurz et al, 
2018 (79)
Retrospective N=23 children 
with ESLD with 
clinically 
indicated CT
Control: 2:1 age 
and sex matched 
healthy controls ( 
trauma victims 
with CT)
CT - PMSA at 
L3/4 and L4/5 
• Children with ESLD have a smaller 
PMSA than healthy controls.
• The PMSA is independent of 






Retrospective N=81 subjects 
with organ failure 
– ESLD (35), 
ESRD (20), IF 
(26) 
Control (39)
CT - PMSA at 
L2/3 
Reduction in muscle mass (ESLD 23%, ESRD 
19%, IF 24%) vs. healthy controls
Serum total protein and albumin, and BMI, 
fail to fully characterize malnutrition in 
chronically ill children
CT, computed tomography; DEXA, dual energy X-ray absorptiometry; ESLD, end stage liver 
disease; ESRD, end stage renal disease; IF, intestine failure; LOS, length of stay; LT, liver 
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Figure Legends
Figure 1. Total Muscle Area Quantification at the Level of 3rd.  Lumbar Vertebra using 
Abdominal CT Images from Two Male Patients with Cirrhosis.
Figure 1 A and B, respectively, present a patient who had low SMI (46 cm2/m2) and high SMI (60 
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